GlassScriptPhysician profile
Rachel Lamonica
NPI 1114127735
$3,214.76
in general payments reported to CMS, 2019-2025
14 companies · $2,537 in 2025
The $2,537 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.81 · 2020: $68.01 · 2021: $273 · 2022: $126 · 2023: $31.10 · 2024: $100 · 2025: $2,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,435 · Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,435.00 |
| Food and Beverage | $233.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,435.00 | 2025 | |
| Abbvie INC. | $295.77 | 2019-2022 | |
| Pfizer INC. | $107.31 | 2020-2024 | |
| Gynesonics, INC. | $84.31 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $73.13 | 2025 | Acessa Provu System |
| Duchesnay USA Incorporated | $40.74 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $34.35 | 2019-2020 | |
| Applied Medical Resources Corporation | $31.10 | 2023 | Gelpoint V-Path |
| Intuitive Surgical, INC. | $28.98 | 2025 | |
| Exeltis, USA INC. | $20.04 | 2021 | |
| Therapeuticsmd, INC. | $19.47 | 2022 | |
| Myovant Sciences INC. | $15.28 | 2021 | |
| Mayne Pharma Commercial LLC | $15.22 | 2022 | |
| Avion Pharmaceuticals | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Lamonica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.